American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Akebia Therapeutics, Inc.

AKBA Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

AKBA historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of AKBA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
AKBA Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
AKBA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AKBA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in AKBA holdings by institutional investors

Insider Trading

Quarterly net insider trading by AKBA's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $360,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $480,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $260,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $280,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
  • $460,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
  • $300,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid
  • $240,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
  • $280,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
  • $260,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $230,000 Jan 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $240,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $310,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $310,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $300,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $320,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $320,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $270,000 Jan 20, 2022 Issue: None
  • $300,000 Oct 20, 2021 Issue: None
  • $400,000 Jul 20, 2021 Issue: None
  • $340,000 Apr 20, 2021 Issue: None
  • $310,000 Jan 21, 2021 Issue: None
  • $340,000 Oct 20, 2020 Issue: None
  • $510,000 Jul 20, 2020 Issue: None
  • $450,000 Apr 20, 2020 Issue: None
  • $300,000 Jan 21, 2020 Issue: None
  • $420,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues
  • $650,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $440,000 Apr 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $140,000 Jan 22, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
  • $90,000 Oct 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
Revolving Door

Former government officials who have lobbied for AKBA

19 former government officials from 15 congressional offices at 4 lobbying firms have lobbied for AKBA, most recently Jul 20, 2026.

  • Scott L. Klug
    Robert Wood House Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug Formerly with Scott L. Klug · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Bill Cassidy
    Robb Walton Senate Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes Formerly with Bill Cassidy · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Tom Bliley
    Brent Del Monte House Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee Formerly with Tom Bliley · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Debbie Wasserman Schultz
    Daniel Farmer House Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space Formerly with Debbie Wasserman Schultz · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Jimmy Panetta
    Joel Bailey House COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall Formerly with Jimmy Panetta · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Marsha Blackburn
    Chris Kelly Senate Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. Blackburn Formerly with Marsha Blackburn · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Charlie Chapman House Policy Advisor, HHS; Special Asst, HHS; Prof Staff Member, House Budget Committee; LA, House Budget Committee; Staff Asst, House Ways and Means Committee; Intern, House Ways and Means Committee Formerly Policy Advisor, HHS; Special Asst, HHS; Prof Staff Member, House Budget Committe · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Ron Wyden
    Raghav Aggarwal Senate Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior Formerly with Ron Wyden · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
See all 19 on the Revolving Door dashboard
Corporate Lobbying

AKBA Estimated quarterly lobbying spending

Revenue Breakdown

AKBA Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
AKBA Income Statement
AKBA Balance Sheet
AKBA Cash Flow
U.S. Patents

New AKBA patent grants

  • Patent Title: Phd inhibitor compounds, compositions, and their use Aug. 11, 2026
  • Patent Title: Therapeutic methods using vadadustat Aug. 04, 2026
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)aminojalkanoic acids, esters and amides Jul. 07, 2026
  • Patent Title: Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer May. 19, 2026
  • Patent Title: Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative Apr. 28, 2026
  • Patent Title: Compositions and methods for treating anemia Mar. 10, 2026
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Nov. 25, 2025
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Sep. 23, 2025
  • Patent Title: Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid Apr. 08, 2025
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 30, 2024
  • Patent Title: Compositions and methods for treating anemia Jan. 02, 2024
  • Patent Title: Compositions and methods for treating anemia Dec. 19, 2023
  • Patent Title: Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid Aug. 01, 2023
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 04, 2023
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid Dec. 13, 2022
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Aug. 30, 2022
  • Patent Title: Compositions and methods for treating anemia May. 10, 2022
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Mar. 08, 2022
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 20, 2021
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Aug. 11, 2020
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Aug. 04, 2020
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Mar. 24, 2020
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jun. 18, 2019
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Apr. 02, 2019
  • Patent Title: Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof Dec. 11, 2018
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Dec. 11, 2018
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jun. 05, 2018
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Oct. 03, 2017
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 11, 2017
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Mar. 21, 2017
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Sep. 29, 2015
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 27, 2015
  • Patent Title: Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer Oct. 21, 2014
  • Patent Title: Prolyl hydroxylase inhibitors and method of use May. 13, 2014
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Dec. 03, 2013
  • Patent Title: Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase Aug. 20, 2013
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 01, 2013
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Dec. 04, 2012
  • Patent Title: N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones Mar. 13, 2012
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to AKBA from public contracts

AKBA News

Recent insights relating to AKBA

CNBC Recommendations

Recent picks made for AKBA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AKBA

AKBA Analyst Ratings

AKBA Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
AKBA Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $AKBA stock a Buy, Sell, or Hold?

  • What is the price target for $AKBA stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

AKBA Top Shareholders
Shareholder
Shares Held
AKBA Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $AKBA stock?

  • Who owns the most shares of $AKBA stock?

  • What funds own $AKBA stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

AKBA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AKBA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About AKBA

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

  • Address Cambridge, MA
  • Market Cap 271.6 million
  • Employees 194
  • Industrial Classification Pharmaceutical Preparations

Akebia Therapeutics, Inc. (AKBA) Historical Stock Prices

Akebia Therapeutics, Inc. (AKBA) closed at $0.9800 on September 22, 2026. Over the past year its adjusted close ranged from $0.8440 to $3.17. Daily prices go back to March 20, 2014, 3,146 trading days in all.

  • 1 month+8.10%
  • 3 months-10.91%
  • Year to date-39.13%
  • 1 year-64.87%
  • 3 years-16.95%
  • 5 years-66.32%
  • Max-96.33%
See every congressional and insider trade on the AKBA price chart

Quiver Premium charts AKBA's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 22, 2026 0.9500 1.00 0.9395 0.9800 0.9800 5,111,315
Sep 21, 2026 0.9270 0.9460 0.9178 0.9385 0.9385 11,093,411
Sep 18, 2026 0.8900 0.9266 0.8800 0.9157 0.9157 7,372,561
Sep 17, 2026 0.9256 0.9401 0.8702 0.8955 0.8955 8,717,316
Sep 16, 2026 0.9082 0.9362 0.8952 0.9178 0.9178 7,503,792
Sep 15, 2026 0.9617 0.9770 0.9026 0.9030 0.9030 5,778,790
Sep 14, 2026 0.9520 1.02 0.9026 0.9629 0.9629 8,833,018
Sep 11, 2026 0.9700 0.9828 0.9512 0.9517 0.9517 6,141,452
Sep 10, 2026 0.9500 0.9677 0.9312 0.9465 0.9465 4,921,838
Sep 9, 2026 1.03 1.05 0.9500 0.9539 0.9539 4,879,944
Sep 8, 2026 0.9616 1.03 0.9528 1.03 1.03 3,064,909
Sep 4, 2026 0.9880 0.9961 0.9471 0.9747 0.9747 8,347,916
Sep 3, 2026 0.9999 1.00 0.9615 0.9833 0.9833 7,456,779
Sep 2, 2026 0.9500 1.01 0.9474 0.9803 0.9803 12,862,353
Sep 1, 2026 0.9099 0.9472 0.9099 0.9447 0.9447 12,453,269
Aug 31, 2026 0.8800 0.9349 0.8550 0.9188 0.9188 15,180,053
Aug 28, 2026 0.9350 0.9400 0.8650 0.8786 0.8786 10,188,404
Aug 27, 2026 0.9100 0.9600 0.9056 0.9398 0.9398 13,288,268
Aug 26, 2026 0.9570 0.9570 0.8762 0.9065 0.9065 14,030,629
Aug 25, 2026 0.9000 0.9630 0.9000 0.9584 0.9584 11,342,585
Aug 24, 2026 0.9078 0.9106 0.8722 0.9006 0.9006 8,125,287
Aug 21, 2026 0.9249 0.9550 0.9054 0.9066 0.9066 6,450,124
Aug 20, 2026 0.8800 0.9298 0.8722 0.9194 0.9194 13,718,542
Aug 19, 2026 0.8518 0.8977 0.8500 0.8854 0.8854 9,875,848
Aug 18, 2026 0.8569 0.8626 0.8382 0.8518 0.8518 1,955,461
Aug 17, 2026 0.8700 0.8800 0.8140 0.8600 0.8600 4,263,932
Aug 14, 2026 0.8700 0.8882 0.8581 0.8728 0.8728 2,087,494
Aug 13, 2026 0.9046 0.9490 0.8641 0.8696 0.8696 4,092,739
Aug 12, 2026 0.8724 0.9100 0.8670 0.8932 0.8932 4,554,986
Aug 11, 2026 0.8400 0.8849 0.8400 0.8665 0.8665 3,793,849
Aug 10, 2026 0.9000 0.9090 0.8367 0.8440 0.8440 8,489,857
Aug 7, 2026 0.9610 0.9620 0.8862 0.9099 0.9099 10,934,392
Aug 6, 2026 0.9021 1.01 0.8500 0.9544 0.9544 17,685,523
Aug 5, 2026 1.32 1.35 1.28 1.29 1.29 4,527,749
Aug 4, 2026 1.31 1.35 1.31 1.32 1.32 2,695,653
Aug 3, 2026 1.31 1.34 1.29 1.31 1.31 2,095,873
Jul 31, 2026 1.34 1.35 1.29 1.32 1.32 2,057,838
Jul 30, 2026 1.24 1.36 1.24 1.35 1.35 3,117,062
Jul 29, 2026 1.26 1.28 1.24 1.26 1.26 1,961,989
Jul 28, 2026 1.28 1.29 1.22 1.27 1.27 1,667,111
Jul 27, 2026 1.24 1.30 1.24 1.28 1.28 1,859,289
Jul 24, 2026 1.22 1.24 1.20 1.22 1.22 1,496,092
Jul 23, 2026 1.23 1.25 1.19 1.22 1.22 1,626,715
Jul 22, 2026 1.31 1.31 1.25 1.26 1.26 2,159,861
Jul 21, 2026 1.27 1.33 1.27 1.30 1.30 1,775,666
Jul 20, 2026 1.33 1.38 1.26 1.28 1.28 2,940,760
Jul 17, 2026 1.37 1.41 1.34 1.34 1.34 2,524,964
Jul 16, 2026 1.37 1.41 1.34 1.40 1.40 3,057,190
Jul 15, 2026 1.39 1.40 1.36 1.38 1.38 1,713,019
Jul 14, 2026 1.39 1.42 1.38 1.40 1.40 2,882,518
Jul 13, 2026 1.37 1.39 1.34 1.38 1.38 3,386,190
Jul 10, 2026 1.43 1.44 1.36 1.40 1.40 4,152,407
Jul 9, 2026 1.41 1.46 1.35 1.43 1.43 4,538,614
Jul 8, 2026 1.34 1.42 1.33 1.42 1.42 6,593,780
Jul 7, 2026 1.30 1.39 1.29 1.36 1.36 5,861,432
Jul 6, 2026 1.25 1.33 1.23 1.30 1.30 6,339,429
Jul 2, 2026 1.22 1.24 1.16 1.24 1.24 4,198,654
Jul 1, 2026 1.15 1.25 1.15 1.21 1.21 6,050,454
Jun 30, 2026 1.28 1.29 1.11 1.14 1.14 6,941,760
Jun 29, 2026 1.14 1.16 1.09 1.11 1.11 3,574,774
Jun 26, 2026 1.04 1.14 1.03 1.14 1.14 11,583,414
Jun 25, 2026 1.04 1.08 1.03 1.04 1.04 3,211,392
Jun 24, 2026 1.10 1.12 1.05 1.06 1.06 3,980,672
Jun 23, 2026 1.09 1.14 1.09 1.10 1.10 2,438,011
Jun 22, 2026 1.08 1.14 1.07 1.09 1.09 5,081,424
Jun 18, 2026 1.05 1.08 0.9960 1.07 1.07 22,933,787
Jun 17, 2026 0.9889 1.05 0.9801 1.02 1.02 3,953,586
Jun 16, 2026 0.9233 1.02 0.9202 0.9840 0.9840 8,095,836
Jun 15, 2026 0.9318 0.9423 0.9000 0.9387 0.9387 5,536,027
Jun 12, 2026 0.8901 0.9591 0.8838 0.9245 0.9245 5,250,278
Jun 11, 2026 0.8601 0.9259 0.8396 0.8994 0.8994 16,696,128
Jun 10, 2026 0.9200 0.9589 0.8227 0.8729 0.8729 7,210,106
Jun 9, 2026 0.9484 0.9598 0.9028 0.9200 0.9200 2,077,653
Jun 8, 2026 0.9517 0.9700 0.9000 0.9356 0.9356 2,488,811
Jun 5, 2026 0.9636 0.9868 0.9288 0.9353 0.9353 1,848,131
Jun 4, 2026 0.9683 0.9999 0.9601 0.9703 0.9703 2,392,948
Jun 3, 2026 0.9364 0.9698 0.9200 0.9697 0.9697 4,549,569
Jun 2, 2026 1.01 1.02 0.9102 0.9364 0.9364 7,220,245
Jun 1, 2026 1.03 1.04 1.00 1.02 1.02 2,756,683
May 29, 2026 1.04 1.05 1.02 1.02 1.02 2,708,651
May 28, 2026 1.04 1.07 1.01 1.05 1.05 2,955,183
May 27, 2026 1.05 1.08 1.03 1.03 1.03 2,738,283
May 26, 2026 1.02 1.08 1.02 1.04 1.04 2,981,843
May 22, 2026 1.01 1.05 1.00 1.02 1.02 2,321,445
May 21, 2026 1.00 1.07 0.9900 1.02 1.02 5,545,347
May 20, 2026 0.9000 1.02 0.8953 1.01 1.01 18,782,800
May 19, 2026 0.9763 1.01 0.8750 0.8951 0.8951 15,501,837
May 18, 2026 1.06 1.09 1.00 1.01 1.01 6,631,552
May 15, 2026 1.14 1.14 1.06 1.06 1.06 4,820,193
May 14, 2026 1.17 1.19 1.13 1.13 1.13 4,085,915
May 13, 2026 1.17 1.20 1.16 1.18 1.18 4,081,191
May 12, 2026 1.17 1.23 1.17 1.18 1.18 4,573,614
May 11, 2026 1.15 1.23 1.14 1.15 1.15 5,541,735
May 8, 2026 1.17 1.20 1.12 1.16 1.16 4,397,994
May 7, 2026 1.14 1.23 1.13 1.18 1.18 11,754,313
May 6, 2026 1.47 1.53 1.46 1.48 1.48 3,994,004
May 5, 2026 1.52 1.54 1.43 1.45 1.45 2,375,116
May 4, 2026 1.41 1.53 1.41 1.50 1.50 3,274,406
May 1, 2026 1.40 1.44 1.38 1.40 1.40 2,575,653
Apr 30, 2026 1.39 1.41 1.36 1.38 1.38 1,291,839
Apr 29, 2026 1.41 1.41 1.35 1.36 1.36 2,178,338
Apr 28, 2026 1.44 1.46 1.41 1.42 1.42 1,536,636
Apr 27, 2026 1.43 1.51 1.42 1.42 1.42 2,701,240
Apr 24, 2026 1.42 1.45 1.41 1.43 1.43 2,379,763
Apr 23, 2026 1.43 1.44 1.39 1.43 1.43 2,168,416
Apr 22, 2026 1.42 1.45 1.40 1.42 1.42 1,492,265
Apr 21, 2026 1.45 1.46 1.40 1.41 1.41 1,842,575
Apr 20, 2026 1.41 1.45 1.40 1.43 1.43 1,971,579
Apr 17, 2026 1.38 1.45 1.32 1.41 1.41 4,082,360
Apr 16, 2026 1.54 1.56 1.35 1.35 1.35 5,257,171
Apr 15, 2026 1.57 1.59 1.53 1.55 1.55 2,092,825
Apr 14, 2026 1.48 1.56 1.47 1.56 1.56 2,259,199
Apr 13, 2026 1.40 1.47 1.39 1.47 1.47 1,738,757
Apr 10, 2026 1.41 1.46 1.38 1.40 1.40 2,051,361
Apr 9, 2026 1.42 1.45 1.41 1.41 1.41 1,280,524
Apr 8, 2026 1.41 1.47 1.40 1.43 1.43 2,524,000
Apr 7, 2026 1.32 1.39 1.30 1.38 1.38 2,363,711
Apr 6, 2026 1.37 1.40 1.32 1.32 1.32 2,362,249
Apr 2, 2026 1.39 1.40 1.35 1.38 1.38 1,879,434
Apr 1, 2026 1.40 1.46 1.40 1.41 1.41 1,853,857
Mar 31, 2026 1.34 1.40 1.34 1.39 1.39 1,898,055
Mar 30, 2026 1.34 1.35 1.30 1.32 1.32 2,639,500
Mar 27, 2026 1.37 1.38 1.32 1.34 1.34 2,635,272
Mar 26, 2026 1.39 1.44 1.36 1.39 1.39 1,818,603
Mar 25, 2026 1.40 1.42 1.36 1.39 1.39 1,885,264
Mar 24, 2026 1.37 1.40 1.33 1.36 1.36 2,408,342
Mar 23, 2026 1.43 1.45 1.39 1.40 1.40 1,946,782
Mar 20, 2026 1.42 1.46 1.39 1.42 1.42 7,623,383
Mar 19, 2026 1.41 1.44 1.39 1.42 1.42 1,977,363
Mar 18, 2026 1.48 1.51 1.41 1.44 1.44 2,905,263
Mar 17, 2026 1.52 1.56 1.48 1.49 1.49 3,166,287
Mar 16, 2026 1.48 1.53 1.46 1.51 1.51 2,979,615
Mar 13, 2026 1.41 1.52 1.40 1.46 1.46 3,751,038
Mar 12, 2026 1.40 1.42 1.34 1.40 1.40 3,302,992
Mar 11, 2026 1.38 1.40 1.33 1.40 1.40 2,167,075
Mar 10, 2026 1.36 1.39 1.33 1.38 1.38 2,520,204
Mar 9, 2026 1.26 1.37 1.25 1.35 1.35 2,428,401
Mar 6, 2026 1.23 1.28 1.21 1.27 1.27 2,462,231
Mar 5, 2026 1.23 1.24 1.18 1.19 1.19 2,889,417
Mar 4, 2026 1.23 1.28 1.22 1.25 1.25 1,917,967
Mar 3, 2026 1.23 1.27 1.21 1.22 1.22 3,815,423
Mar 2, 2026 1.27 1.30 1.24 1.26 1.26 3,001,393
Feb 27, 2026 1.30 1.34 1.26 1.31 1.31 6,997,538
Feb 26, 2026 1.47 1.51 1.26 1.32 1.32 5,001,596
Feb 25, 2026 1.25 1.27 1.20 1.21 1.21 3,090,420
Feb 24, 2026 1.21 1.27 1.19 1.24 1.24 2,492,341
Feb 23, 2026 1.19 1.26 1.18 1.21 1.21 2,310,524
Feb 20, 2026 1.18 1.19 1.14 1.18 1.18 2,541,127
Feb 19, 2026 1.18 1.19 1.15 1.18 1.18 2,053,315
Feb 18, 2026 1.19 1.22 1.17 1.18 1.18 1,815,568
Feb 17, 2026 1.21 1.24 1.15 1.20 1.20 4,876,017
Feb 13, 2026 1.35 1.37 1.20 1.21 1.21 6,044,422
Feb 12, 2026 1.55 1.60 1.33 1.36 1.36 6,830,646
Feb 11, 2026 1.53 1.56 1.45 1.55 1.55 4,503,859
Feb 10, 2026 1.50 1.54 1.45 1.51 1.51 7,114,037
Feb 9, 2026 1.37 1.51 1.33 1.50 1.50 3,893,763
Feb 6, 2026 1.36 1.40 1.33 1.39 1.39 3,420,972
Feb 5, 2026 1.36 1.39 1.35 1.38 1.38 3,271,575
Feb 4, 2026 1.42 1.42 1.35 1.37 1.37 3,004,651
Feb 3, 2026 1.39 1.44 1.37 1.41 1.41 2,363,493
Feb 2, 2026 1.39 1.43 1.36 1.38 1.38 3,808,797
Jan 30, 2026 1.47 1.48 1.40 1.41 1.41 2,307,840
Jan 29, 2026 1.46 1.48 1.42 1.45 1.45 1,812,329
Jan 28, 2026 1.52 1.53 1.44 1.45 1.45 2,414,699
Jan 27, 2026 1.43 1.52 1.39 1.51 1.51 2,578,050
Jan 26, 2026 1.36 1.45 1.35 1.43 1.43 3,259,359
Jan 23, 2026 1.45 1.45 1.35 1.36 1.36 4,175,539
Jan 22, 2026 1.36 1.45 1.36 1.44 1.44 2,373,119
Jan 21, 2026 1.35 1.39 1.33 1.37 1.37 2,105,535
Jan 20, 2026 1.32 1.36 1.30 1.34 1.34 2,463,427
Jan 16, 2026 1.34 1.41 1.33 1.36 1.36 2,766,774
Jan 15, 2026 1.38 1.39 1.33 1.34 1.34 2,478,880
Jan 14, 2026 1.37 1.42 1.34 1.38 1.38 3,215,626
Jan 13, 2026 1.41 1.41 1.31 1.38 1.38 4,544,398
Jan 12, 2026 1.49 1.49 1.36 1.40 1.40 6,780,785
Jan 9, 2026 1.50 1.54 1.48 1.52 1.52 2,647,270
Jan 8, 2026 1.52 1.53 1.49 1.49 1.49 3,581,129
Jan 7, 2026 1.48 1.56 1.48 1.53 1.53 2,699,568
Jan 6, 2026 1.50 1.52 1.46 1.47 1.47 2,871,750
Jan 5, 2026 1.54 1.57 1.50 1.51 1.51 2,156,953
Jan 2, 2026 1.63 1.63 1.55 1.55 1.55 2,531,234
Dec 31, 2025 1.60 1.63 1.58 1.61 1.61 2,270,518
Dec 30, 2025 1.62 1.65 1.58 1.59 1.59 2,802,286
Dec 29, 2025 1.65 1.66 1.61 1.62 1.62 3,284,704
Dec 26, 2025 1.68 1.68 1.64 1.66 1.66 2,195,723
Dec 24, 2025 1.65 1.71 1.64 1.70 1.70 1,508,848
Dec 23, 2025 1.68 1.68 1.60 1.65 1.65 2,752,943
Dec 22, 2025 1.65 1.73 1.64 1.66 1.66 2,834,782
Dec 19, 2025 1.68 1.71 1.66 1.66 1.66 5,352,008
Dec 18, 2025 1.63 1.73 1.62 1.67 1.67 3,421,609
Dec 17, 2025 1.61 1.68 1.61 1.61 1.61 2,333,831
Dec 16, 2025 1.61 1.67 1.60 1.62 1.62 2,526,876
Dec 15, 2025 1.68 1.68 1.59 1.61 1.61 2,064,063
Dec 12, 2025 1.67 1.70 1.65 1.66 1.66 2,110,666
Dec 11, 2025 1.63 1.70 1.62 1.66 1.66 2,541,533
Dec 10, 2025 1.58 1.63 1.56 1.63 1.63 4,573,946
Dec 9, 2025 1.60 1.62 1.55 1.58 1.58 3,089,519
Dec 8, 2025 1.55 1.62 1.53 1.62 1.62 3,701,431
Dec 5, 2025 1.59 1.60 1.53 1.54 1.54 2,202,071
Dec 4, 2025 1.57 1.60 1.53 1.59 1.59 1,998,756
Dec 3, 2025 1.47 1.58 1.46 1.57 1.57 4,130,252
Dec 2, 2025 1.51 1.52 1.45 1.47 1.47 5,970,146
Dec 1, 2025 1.60 1.63 1.50 1.51 1.51 4,627,904
Nov 28, 2025 1.60 1.60 1.54 1.58 1.58 1,193,195
Nov 26, 2025 1.55 1.60 1.52 1.59 1.59 2,416,481
Nov 25, 2025 1.57 1.65 1.56 1.57 1.57 2,542,406
Nov 24, 2025 1.56 1.60 1.53 1.59 1.59 2,815,144
Nov 21, 2025 1.51 1.59 1.49 1.55 1.55 3,176,249
Nov 20, 2025 1.62 1.66 1.52 1.54 1.54 4,039,264
Nov 19, 2025 1.65 1.66 1.57 1.59 1.59 3,981,140
Nov 18, 2025 1.75 1.75 1.61 1.65 1.65 5,558,660
Nov 17, 2025 1.69 1.83 1.67 1.76 1.76 6,184,802
Nov 14, 2025 1.73 1.79 1.64 1.67 1.67 13,654,319
Nov 13, 2025 1.82 1.83 1.75 1.76 1.76 3,767,220
Nov 12, 2025 1.82 1.89 1.77 1.85 1.85 4,436,049
Nov 11, 2025 1.68 1.84 1.67 1.81 1.81 5,189,379
Nov 10, 2025 1.73 1.75 1.57 1.67 1.67 16,762,309
Nov 7, 2025 2.02 2.07 1.96 2.04 2.04 4,475,761
Nov 6, 2025 2.11 2.11 1.98 2.01 2.01 4,130,211
Nov 5, 2025 2.08 2.13 2.06 2.12 2.12 3,070,674
Nov 4, 2025 2.10 2.15 2.07 2.09 2.09 5,465,754
Nov 3, 2025 2.20 2.22 2.06 2.12 2.12 4,254,707
Oct 31, 2025 2.11 2.23 2.07 2.21 2.21 6,112,330
Oct 30, 2025 2.09 2.32 2.06 2.10 2.10 9,161,512
Oct 29, 2025 2.16 2.56 2.08 2.10 2.10 25,769,764
Oct 28, 2025 3.20 3.20 3.07 3.09 3.09 6,811,294
Oct 27, 2025 3.06 3.19 3.05 3.17 3.17 2,387,749
Oct 24, 2025 3.00 3.07 2.98 3.03 3.03 1,353,929
Oct 23, 2025 3.00 3.04 2.96 2.98 2.98 1,524,807
Oct 22, 2025 3.09 3.10 2.93 2.99 2.99 2,603,568
Oct 21, 2025 3.16 3.18 3.06 3.12 3.12 3,393,059
Oct 20, 2025 2.95 3.17 2.93 3.16 3.16 3,366,733
Oct 17, 2025 2.90 2.96 2.87 2.93 2.93 2,045,374
Oct 16, 2025 2.97 3.10 2.89 2.92 2.92 3,116,501
Oct 15, 2025 2.79 2.96 2.79 2.95 2.95 2,954,750
Oct 14, 2025 2.75 2.84 2.70 2.79 2.79 1,652,575
Oct 13, 2025 2.77 2.81 2.69 2.78 2.78 2,401,040
Oct 10, 2025 2.89 2.91 2.75 2.75 2.75 2,920,130
Oct 9, 2025 2.85 2.96 2.85 2.89 2.89 2,108,745
Oct 8, 2025 2.99 3.02 2.83 2.85 2.85 2,576,066
Oct 7, 2025 2.99 2.99 2.88 2.95 2.95 3,407,509
Oct 6, 2025 2.84 3.01 2.81 2.97 2.97 4,210,566
Oct 3, 2025 2.72 2.92 2.71 2.83 2.83 2,868,192
Oct 2, 2025 2.68 2.77 2.66 2.71 2.71 2,626,731
Oct 1, 2025 2.72 2.73 2.67 2.68 2.68 1,997,536
Sep 30, 2025 2.73 2.75 2.66 2.73 2.73 2,534,113
Sep 29, 2025 2.75 2.79 2.70 2.71 2.71 1,419,050
Sep 26, 2025 2.71 2.74 2.67 2.74 2.74 1,944,714
Sep 25, 2025 2.76 2.78 2.69 2.71 2.71 2,626,994
Sep 24, 2025 2.85 2.88 2.77 2.77 2.77 1,850,833
Sep 23, 2025 2.79 2.90 2.78 2.83 2.83 2,204,118
Sep 22, 2025 2.78 2.81 2.74 2.79 2.79 1,954,926

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Akebia Therapeutics, Inc. Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at AKBA, per a recent SEC DEF 14A filing. We estimate that the median employee at Akebia Therapeutics, Inc. is paid $248,328.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation